Page 4 - Shimadzu Journal vol.2 Issue4

Insight from Customer 105

F, Le Meur Y, Marquet P, Rousseau A. Exposure to mycophenolic
(5)Daher Abdi Z, Prémaud A, Essig M, Alain S, Munteanu E, Garnier
acid better predicts immunosuppressive efficacy than exposure

Pharmacol Ther. 2014 Oct; 96(4):508-15. to calcineurin inhibitors in renal transplant patients. Clin (6)Gauthier T, Piver P, Pichon N, Bibes R, Guillaudeau A, Piccardo A, Pesteil F, Tricard J, Gardet E, Laskar M, Lalloué F, Marquet P, Aubard Y. Uterus retrieval process from brain dead donors. Fertil Steril. 2014 Aug; 102(2):476-82. (7)Monchaud C, Marin B, Estenne M, Preux PM, Marquet P; the Delphi-Lung Transplant Group(). Consensus Conference on a Composite Endpoint for Clinical Trials on Immunosuppressive Drugs in Lung Transplantation. Transplantation. 2014 Jun 20. (8)Daher Abdi Z, Lavau-Denes S, Prémaud A, Urien S, Sauvage FL, Martin J, Leobon S, Marqu

Shimadzu: Finally, could you please share any requests that you have with respect to instrument vendors? Prof. MARQUET The main suggestion I would make to scientific instrument vendors is not to neglect support and development assistance to customers. In a world where everyone is increasingly pressed for time, method implementation is a very important asset to stand out from other vendors. Shimadzu: It is important to know what you think of us and our collaboration. We will strive to meet your requests more than ever. Thank you very much. Pierre MARQUET, Jean-Michel GAULLIER, Denis RAFFIER (from left to right) Here are his 2014 publications: (1)Gauthier T, Piver P, Pichon N, Essig M, Marquet P,

head of the INSERM research unit UMR 850 in “Pharmacology of immunosuppressive drugs in transplantation” (INSERM is
the University Hospital of Limoges, France. His research area is pharmacology and toxicology. Since 2007, he has been the
We interviewed Professor Pierre MARQUET, head of the Pharmacology, Toxicology and Pharmacovigilance department at
Professor MARQUET and Shimadzu started a collaborative project in 2013 that has already yielded several achievements.

Shimadzu: Why are you interested in such developments? What is your goal? Prof. MARQUET For most of these newly developed methods, the LCMS-8050 replaces more than one GC-MS. The latter requires long but also manual sample preparation. Budget restrictions being a strong reality in French hospitals, the lack of technicians is sorely felt. This technological switch allows us to maintain and develop our activity despite fewer technicians, while reporting the results faster. Another focus that we have in mind when doing new developments is the introduction of new illicit or therapeutic drugs to our panels of tests. Shimadzu: How are our instruments helping you? Prof. MARQUET

global w430×h280 Insight from Customer Professor Pierre MARQUET of University Hospital of Limoges the French National Institute of Medical and Health Research). Shimadzu: Professor MARQUET, thank you very much for taking some time for this interview. First of all, could you tell us about the background of this collaborative research? Why did you choose Shimadzu? Prof. MARQUET The Laboratory of Pharmacology and Toxicology of the University Hospital of Limoges is one of the largest in France. It is divided into transplantation research activities (INSERM unit created in 2007) and clinical activities. In 2013, Shimadzu proposed to set up collaboration with a one-year loan of a triple quadrupole LCMS-8040. Due to the